BPT is a company focused on the development and commercialisation of a novel proprietary drug delivery platform called ARISE (Atomised Rapid Injection for Solvent Extraction).
ARISE is a second generation, super critical fluid (SCF) solvent extraction technology that generates, from pharmaceutical mixtures, aerodynamic, nanosized particulates with improved surface area and particle size distribution. This process provides an effective means for innovative drug delivery for those drugs that are currently available either as an oral or as an intravenous formulation but for which direct pulmonary exposure would be of clinical benefit.
The ARISE process can be applied to proteins as well as small molecules, and laboratory proof of concept has been demonstrated with insulin and tobramycin.
Number of employees: 1-10
Main business focus/
Listing by sector:
- Drug Discovery & Development
|Contact person||Professor Neil Foster|
|State||New South Wales|